Pacific Biosciences Of California, INC. (PACB) — 10-Q Filings

All 10-Q filings from Pacific Biosciences Of California, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

PacBio's Q3 Loss Widens Amid Soaring Intangible Asset Amortization — Nov 6, 2025 Risk: high
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported a significant net loss of $506.005 million for the nine months ended September 30, 2025, a substantial i
PacBio's Q2 Revenue Jumps 33% on Strong Product Sales — Aug 7, 2025 Risk: medium
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported total revenue of $40.0 million for the second quarter of 2025, a significant increase from $30.0 million
PacBio Files Q1 2025 10-Q — May 12, 2025 Risk: medium
Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational upd
PacBio Files Q3 2024 10-Q with Revenue Details — Nov 12, 2024 Risk: low
Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending September 30, 2024. The company reported revenue for the third quarter of 20
PacBio Files Q2 2024 10-Q with Revenue Details — Aug 9, 2024 Risk: medium
Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending June 30, 2024. The company reported revenue for the second quarter of 2024 a
PacBio Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: high
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Total revenue for the three months ended March 31, 2

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX